Haematopoietic cell transplantation at the Institute of Haematology and Blood Transfusion (1986–2016)
Authors:
A. Vítek; J. Vydra; M. Marková-Šťastná; L. Nováková; V. Válková; P. Cetkovský
Authors‘ workplace:
Ústav hematologie a krevní transfuze, Praha
Published in:
Transfuze Hematol. dnes,23, 2017, No. Supplementum1, p. 54-66.
Category:
Overview
The hematopoietic cell transplantation (HCT) program at the Institute of Haematology and Blood transfusion (ÚHKT) was initiated in 1986 and 1250 transplantations had been performed by the end of 2016. Over this period, HLA matched sibling donor transplantations were followed by unrelated donor HCT and later haploidentical HCT. Outcome of HCT has continuously improved leading to improved survival of transplanted patients. Our results are currently comparable with those from other experienced transplant centres. Annually, the ÚHKT performs the highest number allogeneic HCT compared to the other transplant centres in the Czech Republic, thus significantly contributing to the fact that the number of allo-HCT per 10 mil. inhabitants is the same as in Western European states. Currently we can offer transplantation to all patients in need of this therapeutic approach in the Czech Republic. This paper presents the results of HCT performed at the ÚHKT.
KEY WORDS:
haematopoietic cell transplantation – UHKT results in selected diagnoses
Sources
1. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016;127(1):62–70.
2. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015;50:1037–1056.
3. Martino R, de Wreede L, Fiocco M, et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with < 10% BM blasts: a report from EBMT. Bone Marrow Transplant 2013;48:761–770.
4. Krejčí M, Sedláček P, Jindra P, et al. Indikace k alogenním a autologním transplantacím krvetvorných buněk v ČR v roce 2016: doporučení Transplantační sekce České hematologické společnosti ČLS JEP a České onkologické společnosti ČLS JEP. Transfuze Hematol dnes 2016;22(2):127–150.
5. Greenberg PL, Tuechler H, Schanz J, Sanz G. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
6. de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 2017;129(13):1753–1762.
7. Giebel S, Labopin M, Gorin NC, et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Cancer 2014;50:411–417.
8. Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood 2013;121:339–350.
9. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.
10. Helhmann R, Berger U, Pfirrmann M. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007;109:4686–4692.
11. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 1998;352:1087–1092.
12. Gratwohl A, Pfirrmann M, Zander A, et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia 2016;30(3):562–569
13. Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010;95:224–231.
14. Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008;112:3500–3507.
15. Passamonti F, Cervantes F, Vannucchi AM, et al: A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703–1708.
16. Gangat N, Caramazza D, Vaidya R, et al. DIPSS Plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2010;29:392–397.
17. van Kampen RJW, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin‘s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation registry. J Clin Oncol 2011;29:1342–1348.
18. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 2014;124:2354–2361.
19. Pytlik R, Belada D, Kubackova K, et al. Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial. Leuk Lymphoma 2015;56:57–64.
20. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540–1545.
21. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the Rituximab era. J Clin Oncol 2010; 28:4184–4190.
22. Al Khabori M, de Almeida JR, Guyatt GH, et al. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2012;104:18–28.
23. Montoto S, Corradini P, Dreyling M, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica 2013;98:1014–1021.
24. Robinson S, Dreger P, Caballero D, et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplanta-tion in mantle cell lymphoma. Leukemia 2015;29:464–473.
25. Vaughn JE, Sorror ML, Storer BE, et al. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer 2015;121:3709–3716.
26. d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30:3093–3099.
27. Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27:106–113.
28. Dodero A, Spina F, Narni F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012;26:520–526.
29. Duarte RF, Boumendil A, Onida F, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European Society for Blood and Marrow Transplantation Lymphoma Working Party extended analysis. J Clin Oncol 2014; 32:3347–3348.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2017 Issue Supplementum1
Most read in this issue
- Dysfibrinogenaemia and afibrinogenaemia in the Czech Republic
- Transfusion and immunohematology at the Institute of Haematology and Blood Transfusion
- Centre for rare disorders of haematopoiesis at the Institute of Haematology and Blood Transfusion
- Functional consequences of mutations in the nucleophosmin gene in acute myeloid leukaemia